Japan Orthobiologics Market Outlook to 2025
Summary
GlobalData’s new report, Japan Orthobiologics Market Outlook to 2025, provides key market data on the Japan Orthobiologics market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market categories - Bone Grafts and Substitutes, Bone Growth Stimulators, Soft Tissue Biologics and Viscosupplementation.
The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
- Market size and company share data for Orthobiologics market categories - Bone Grafts and Substitutes, Bone Growth Stimulators, Soft Tissue Biologics and Viscosupplementation.
- Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2015 to 2025.
- 2017 company share and distribution share data for Orthobiologics market.
- Global corporate-level profiles of key companies operating within the Japan Orthobiologics market.
- Key players covered include Medtronic plc, Sanofi, Stryker Corp and Others.
- Develop business strategies by identifying the key market categories poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
- 2.1 What Is This Report About?
- 2.2 Orthobiologics Market Segmentation
- 2.3 Definitions of Markets Covered in the Report
- 3 Orthobiologics Market, Japan
- 3.1 Orthobiologics Market, Japan, Revenue ($m), 2015-2025
- 3.1.1 Bone Grafts and Substitutes Market, Japan, Revenue ($m), by Segment, 2015-2025
- 3.1.2 Bone Growth Stimulators Market, Japan, Revenue ($m), by Segment, 2015-2025
- 3.1.3 Soft Tissue Biologics Market, Japan, Revenue ($m), by Segment, 2015-2025
- 3.1.4 Viscosupplementation Market, Japan, Revenue ($m), by Segment, 2015-2025
- 3.2 Orthobiologics Market, Japan, Volume (Units), 2015-2025
- 3.2.1 Bone Grafts and Substitutes Market, Japan, Volume (Units), by Segment, 2015-2025
- 3.2.2 Bone Growth Stimulators Market, Japan, Volume (Units), by Segment, 2015-2025
- 3.2.3 Soft Tissue Biologics Market, Japan, Volume (Units), by Segment, 2015-2025
- 3.2.4 Viscosupplementation Market, Japan, Volume (Units), by Segment, 2015-2025
- 3.3 Orthobiologics Market, Japan, Average Price ($), 2015-2025
- 3.4 Orthobiologics Market, Japan, Distribution Share by Revenue ($m), 2017
- 3.5 Orthobiologics Market, Japan, Company Share by Revenue ($m), 2017
- 4 Overview of Key Companies in Japan, Orthobiologics Market
- 4.1 Seikagaku Corp
- 4.1.1 Company Overview
- 4.2 Chugai Pharmaceutical Co Ltd
- 4.2.1 Company Overview
- 4.3 DePuy Synthes Inc
- 4.3.1 Company Overview
- 4.4 Stryker Corp
- 4.4.1 Company Overview
- 4.5 Medtronic Plc
- 4.5.1 Company Overview
- 4.6 Sanofi
- 4.6.1 Company Overview
- 4.7 Zimmer Biomet Holdings Inc
- 4.7.1 Company Overview
- 5 Orthobiologics Market Pipeline Products
- 6 Financial Deals Landscape
- 6.1 Partnerships
- 6.1.1 Medinet Enters into Licensing Agreement with Histogenics
- 7 Recent Developments
- 7.1 Financial Announcements
- 7.1.1 Apr 26, 2018: Kyocera Announces Financial Results for Year Ended March 31, 2018
- 7.1.2 Mar 29, 2018: Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
- 7.1.3 Mar 28, 2018: Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx, for patients with previously treated advanced Hepatocellular Carcinoma (HCC)
- 7.1.4 Mar 27, 2018: Constant Pharmaceuticals Announces European Patent Issuance for TXA127 in Treatment of Stroke
- 7.1.5 Mar 22, 2018: SelectHealth Signs Value-based Contract With Novo Nordisk
- 8 Appendix
- 8.1 Research Methodology
- 8.1.1 Coverage
- 8.1.2 Secondary Research
- 8.1.3 Primary Research
- 8.1.4 Market Modeling and Forecasting
- 8.1.5 Company Share Analysis
- 8.1.6 Distribution Share Analysis
- 8.1.7 Benchmarking
- 8.2 GlobalData Consulting
- 8.3 Contact Us
- 8.4 Disclaimer
- 1.1 List of Tables
- Table 1: Orthobiologics Market, Japan, Revenue ($m), USD Constant, 2015-2020
- Table 2: Orthobiologics Market, Japan, Revenue ($m), USD Constant, 2021-2025
- Table 3: Bone Grafts and Substitutes Market, Japan, Revenue ($m), USD Constant, 2015-2020
- Table 4: Bone Grafts and Substitutes Market, Japan, Revenue ($m), USD Constant, 2021-2025
- Table 5: Bone Growth Stimulators Market, Japan, Revenue ($m), USD Constant, 2015-2020
- Table 6: Bone Growth Stimulators Market, Japan, Revenue ($m), USD Constant, 2021-2025
- Table 7: Soft Tissue Biologics Market, Japan, Revenue ($m), USD Constant, 2015-2020
- Table 8: Soft Tissue Biologics Market, Japan, Revenue ($m), USD Constant, 2021-2025
- Table 9: Viscosupplementation Market, Japan, Revenue ($m), USD Constant, 2015-2020
- Table 10: Viscosupplementation Market, Japan, Revenue ($m), USD Constant, 2021-2025
- Table 11: Orthobiologics Market, Japan, Volume (Units), 2015-2020
- Table 12: Orthobiologics Market, Japan, Volume (Units), 2021-2025
- Table 13: Bone Grafts and Substitutes Market, Japan, Volume (Units), 2015-2020
- Table 14: Bone Grafts and Substitutes Market, Japan, Volume (Units), 2021-2025
- Table 15: Bone Growth Stimulators Market, Japan, Volume (Units), 2015-2020
- Table 16: Bone Growth Stimulators Market, Japan, Volume (Units), 2021-2025
- Table 17: Soft Tissue Biologics Market, Japan, Volume (Units), 2015-2020
- Table 18: Soft Tissue Biologics Market, Japan, Volume (Units), 2021-2025
- Table 19: Viscosupplementation Market, Japan, Volume (Units), 2015-2020
- Table 20: Viscosupplementation Market, Japan, Volume (Units), 2021-2025
- Table 21: Orthobiologics Market, Japan, Average Price ($), 2015-2020
- Table 22: Orthobiologics Market, Japan, Average Price ($), 2021-2025
- Table 23: Orthobiologics Market, Japan, Distribution Share by Revenue ($m), USD Constant, 2017
- Table 24: Orthobiologics Market, Japan, Company Share by Revenue ($m), USD Constant, 2017
- Table 25: Orthobiologics Market Pipeline Products
- Table 26: Medinet Enters into Licensing Agreement with Histogenics
- Table 27: Total Number of Primary Research Participants, Orthopedic Devices Market, by Country
- 1.2 List of Figures
- Figure 1: Orthobiologics Market, Japan, Revenue ($m), USD Constant, 2015-2025
- Figure 2: Bone Grafts and Substitutes Market, Japan, Revenue ($m), USD Constant, 2015-2025
- Figure 3: Bone Growth Stimulators Market, Japan, Revenue ($m), USD Constant, 2015-2025
- Figure 4: Soft Tissue Biologics Market, Japan, Revenue ($m), USD Constant, 2015-2025
- Figure 5: Viscosupplementation Market, Japan, Revenue ($m), USD Constant, 2015-2025
- Figure 6: Orthobiologics Market, Japan, Volume (Units), 2015-2025
- Figure 7: Bone Grafts and Substitutes Market, Japan, Volume (Units), 2015-2025
- Figure 8: Bone Growth Stimulators Market, Japan, Volume (Units), 2015-2025
- Figure 9: Soft Tissue Biologics Market, Japan, Volume (Units), 2015-2025
- Figure 10: Viscosupplementation Market, Japan, Volume (Units), 2015-2025
- Figure 11: Orthobiologics Market, Japan, Company Share (%) 2017
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook